Showing 3991-4000 of 4062 results for "".
- Oculus to Present New Formulas for the Pentacam AXLhttps://modernod.com/news/oculus-to-present-new-formulas-for-the-pentacam-axl-advanced-barrett-and-olsen-formulas/2479866/At the ESCRS 2018 in Vienna, Oculus is introducing the advanced Barrett Toric calculator, including the posterior cornea, and the Olsen ray-tracing formula, within the IOL calculator of the Pentacam AXL. Both formulas are available to all Pentacam AXL users in a free software update. The n
- Iridex Announces MicroPulse Treatment Symposium at ESCRShttps://modernod.com/news/iridex-announces-micropulse-treatment-symposium-at-escrs/2479868/Iridex announced they will be hosting a symposium at the Annual Meeting of the European Society for Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria on September 22, 2018. “MicroPulse Technology: Latest Trends in Laser Treatment Choices for Glaucoma and
- Bascom Palmer Treats First US Patient in Nightstar Gene Therapy Clinical Trial for X-Linked Retinitis Pigmentosahttps://modernod.com/news/bascom-palmer-treats-first-us-patient-in-nightstar-gene-therapy-clinical-trial-for-x-linked-retinitis-pigmentosa/2479869/A patient with X-linked retinitis pigmentosa (XLRP) is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. On August 23, Julio Adorno Nieves, 23, of Puerto Rico, became the first U.S. patient to
- Oxurion to Present Scientific Findings Supporting Therapeutic Potential of THR-317 and THR-687 at EURETINAhttps://modernod.com/news/oxurion-to-present-scientific-findings-supporting-therapeutic-potential-of-thr-317-and-thr-687-at-euretina/2479880/Oxurion announced that it will give two presentations at the Euretina International Congress, which is being held in Vienna, Austria, from September 20-23, 2018. The presentation “Anti-inflammatory effects of the PlGF neutralizing antibody THR-317 in patients with diabetic macular edema” w
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- BioAxone BioSciences’ Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Awardhttps://modernod.com/news/bioaxone-biosciences-scientific-advisory-board-member-mark-bear-phd-receives-500000-beckman-argyros-vision-research-award/2479937/BioAxone BioSciences announced that its Scientific Advisory Board member, Mark Bear, PhD, the Picower Professor of Neuroscience at the Massachusetts Institute of Technology, received the prestigious Arnold and Mabel Beckman Foundation 2018 Beckman-Argyros Vision Research Award. This annual
- Mount Sinai Researchers Discover How to Restore Vision Using Retinal Stem Cellshttps://modernod.com/news/mount-sinai-researchers-discover-how-to-restore-vision-using-retinal-stem-cells/2479939/Researchers at Mount Sinai have successfully restored vision in mice through activating retinal stem cells, something that has never been done before. Their study, published in the August 15 online issue of Nature, could transform treatment for patients with retinal degenerative diseases
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit